Arabic Arabic English English French French German German
dark

XPhyto Launches First Commercial Biosensor for Oral Disease

XPhyto Therapeutics Corp. with its partner and acquisition target, 3a-diagnostics GmbH, has successfully registered their first biosensor test in oral inflammation with the German authorities. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)

Next Post

Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021

Related Posts
Total
0
Share